Indication
Heterozygous familial hypercholesterolemia
Heterozygous familial hypercholesterolemia is an inherited genetic metabolic disorder of lipid metabolism characterized by life-long, severely elevated circulating levels of low-density lipoprotein cholesterol. Read more about Heterozygous familial hypercholesterolemia
274 drugs 112 manufacturers
Drugs that treat it
Common Heterozygous familial hypercholesterolemia therapies.
FLUVASTATIN ER (fluvastatin sodium)
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHeterozygous familial hypercholesterolemia is an inherited genetic metabolic disorder of lipid metabolism characterized by life-long, severely elevated circulating levels of low-density lipoprotein cholesterol.
Caused by a single pathogenic variant inherited from one parent—most commonly in the low-density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), or *PCSK9* genes—the condition impairs normal hepatic low-density lipoprotein clearance.
This chronic lipid accumulation affects the vascular and integumentary systems, significantly accelerating systemic atherosclerosis and predisposing affected individuals to premature coronary artery disease, early myocardial infarction, and extravascular deposits such as tendon xanthomas and corneal arcus.
- medlineplus.gov
Heterozygous familial hypercholesterolemia is an inherited genetic metabolic disorder of lipid metabolism characterized by life-long, severely elevated circulating levels of low-density lipoprotein cholesterol Caused by a single pathogenic variant inherited from one parent—most commonly in the low-density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), or *PCSK9* genes—the condition impairs normal hepatic low-density lipoprotein clearance This chronic lipid accumulation affects the vas...
- nih.gov
Heterozygous familial hypercholesterolemia is an inherited genetic metabolic disorder of lipid metabolism characterized by life-long, severely elevated circulating levels of low-density lipoprotein cholesterol
- nih.gov
Caused by a single pathogenic variant inherited from one parent—most commonly in the low-density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), or *PCSK9* genes—the condition impairs normal hepatic low-density lipoprotein clearance
- nih.gov
Caused by a single pathogenic variant inherited from one parent—most commonly in the low-density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), or *PCSK9* genes—the condition impairs normal hepatic low-density lipoprotein clearance This chronic lipid accumulation affects the vascular and integumentary systems, significantly accelerating systemic atherosclerosis and predisposing affected individuals to premature coronary artery disease, early myocardial infarction, and extravascular de...
- nih.gov
This chronic lipid accumulation affects the vascular and integumentary systems, significantly accelerating systemic atherosclerosis and predisposing affected individuals to premature coronary artery disease, early myocardial infarction, and extravascular deposits such as tendon xanthomas and corneal arcus
Personalize your experience
Follow Heterozygous familial hypercholesterolemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.